Carvedilol targets human K2P 3.1 (TASK1) K+ leak channels.
Staudacher K, Staudacher I, Ficker E, Seyler C, Gierten J, Kisselbach J, Rahm AK, Trappe K, Schweizer PA, Becker R, Katus HA, Thomas D.
Staudacher K, et al. Among authors: schweizer pa.
Br J Pharmacol. 2011 Jul;163(5):1099-110. doi: 10.1111/j.1476-5381.2011.01319.x.
Br J Pharmacol. 2011.
PMID: 21410455
Free PMC article.